Key Takeaways: On April 2, 2026, the White House announced 100% tariffs on imported pharmaceutical products and active pharmaceutical ingredients under Section 232. Generic finished drugs are currently exempt, but bulk APIs used by compounding pharmacies are not. Testosterone and estrogen APIs primarily come from China and India. Compounded hormone therapy patients are the most exposed to price increases. The tariffs take effect July 31 for large manufacturers and September 29 for everyone else. Patients who rely on compounded TRT or HRT should understand the supply chain behind their medication and plan accordingly.
What Happened
On April 2, 2026, President Trump signed a proclamation imposing 100% tariffs on imported patented pharmaceuticals and key pharmaceutical inputs under Section 232 of the Trade Expansion Act of 1962. The stated goal is to incentivize domestic pharmaceutical manufacturing and reduce reliance on foreign supply chains.
The tariffs have a phased rollout. The 17 largest pharmaceutical companies face the tariff starting July 31, 2026. All other importers face it starting September 29, 2026. Companies that submit approved US onshoring plans can reduce their rate to 20 percent until April 2030. Companies that negotiate most-favored-nation pricing deals pay zero tariffs until January 2029.
The critical detail for hormone therapy patients: generic finished pharmaceuticals are currently exempt, but bulk active pharmaceutical ingredients are not fully protected. This creates a split impact depending on how your medication is manufactured and sourced.
Why This Matters for TRT and HRT Patients
The United States imports roughly 80 percent of its pharmaceutical ingredients. Testosterone cypionate, testosterone enanthate, estradiol, and progesterone APIs overwhelmingly come from two countries: China and India. India alone produces over 35 percent of the global API supply, and India itself relies on China for approximately 70 percent of its own API feedstock.
This means the raw material that becomes your compounded testosterone vial, your estradiol cream, or your progesterone capsule has likely crossed at least one border subject to the new tariff structure.
Who Gets Hit and Who Does Not
The impact is not uniform. It depends on where your medication sits in the supply chain.
Branded generic manufacturers (Hikma, Sun Pharma, Pfizer, Amneal, Sandoz) that produce finished testosterone cypionate vials and estradiol patches are currently shielded by the generic exemption. Their finished products are exempt from the Section 232 tariff. However, if they import the bulk APIs to manufacture those products domestically, the API input cost still rises. Whether they absorb the increase or pass it through depends on their margin structure and competitive dynamics.
Compounding pharmacies (503A and 503B) are the most exposed. They import bulk APIs directly and compound them into patient-specific prescriptions. There is no generic finished product exemption for bulk powder. A compounding pharmacy that buys testosterone cypionate powder from a Chinese or Indian supplier at a given price will see that cost increase when the tariff takes effect. Compounding pharmacies already operate on thin margins, and the economics make absorption difficult.
Telehealth TRT clinics sit in the middle. Most online TRT clinics partner with compounding pharmacies for their testosterone supply. Some have shifted to branded generics from commercial manufacturers. The ones that rely entirely on compounded medication will face the upstream cost pressure first. Clinics that offer commercially manufactured testosterone cypionate from domestic generic manufacturers have more price stability for now.
What the Research Predicts
A study published in Health Affairs Scholar modeled the impact of API tariffs on the price of US-made generic drugs. Researchers analyzed US importation data from 2019 to 2024 for 17 generic APIs, including estrogen, progesterone, and levothyroxine.
Under the baseline scenario where APIs represent 30 percent of finished drug cost and 100 percent of the tariff is passed through to patients:
A 100 percent worldwide tariff would raise average generic drug prices by 30 percent, or about $21.15 per prescription
A blended tariff based on country-specific rates (China at 54.9%, India at 25%, Europe at 15%) would raise prices by 10 percent, or about $6.22 per prescription
Estrogen specifically showed a 5.3 percent price increase under the blended scenario
The study notes that if suppliers absorb 75 percent of the cost increase rather than passing it through, the patient-facing impact drops by roughly half. But compounding pharmacies -- which run on thinner margins than large generic manufacturers -- have less room to absorb.
The Compounding Pharmacy Problem
Compounding pharmacies are the backbone of the online TRT clinic model. When you sign up with most telehealth TRT providers and receive a multi-dose vial of testosterone cypionate, that vial was likely compounded from bulk API powder imported from overseas.
The compounding pharmacy advantage has always been cost. A compounded testosterone cypionate vial typically costs $30 to $60, compared with $100 to $350 for branded Depo-Testosterone. That cost advantage exists in part because compounding pharmacies source raw API at international market prices.
If the new tariffs add 25 to 100 percent to the API input cost, compounding pharmacies face an impossible choice: absorb the loss, raise prices, or find a domestic API source. Domestic testosterone API manufacturing exists but is limited in scale and typically more expensive at baseline.
For patients, this could mean:
Monthly compounded TRT costs rising $5 to $20 per vial
Some compounding pharmacies discontinuing low-margin hormone products altogether
Clinics shifting patients to commercially manufactured generics
Supply disruptions during the transition period as pharmacies renegotiate supplier contracts
The Estrogen Patch Double Squeeze
The estrogen patch market is already under stress. Prescriptions for estrogen-based therapies among women ages 45 to 54 have increased 184 percent since 2018. Between July 2025 and February 2026 alone, prescriptions rose 20 percent after the FDA removed black-box warnings from hormone therapy products in November 2025.
Five major patch manufacturers -- Amneal, Zydus, Sandoz, Noven, and Viatris -- are all running at full capacity but still falling short of demand. Some estrogen patch doses have been in shortage since January 2026. Industry experts estimate the shortage could last up to three years as production capacity catches up.
Now add tariff pressure on top of the supply-demand imbalance. Estrogen APIs used to manufacture patches domestically face higher import costs. Patch manufacturers operate on low generic margins. The combination of rising input costs and maxed-out production capacity means price stability is unlikely.
Women already struggling to fill estrogen patch prescriptions may see co-pays rise alongside continued availability gaps.
What You Can Do Now
The tariffs do not take effect until late July at the earliest. That gives patients and clinics a window to prepare.
For TRT Patients
Ask your clinic where the testosterone comes from. Specifically, ask whether your vial is compounded from imported bulk API or whether it is a commercially manufactured generic from a domestic company. This determines your tariff exposure.
Compare clinic pricing. Clinics that source from commercial generic manufacturers may hold prices longer than those dependent on compounding pharmacies. Use our clinic comparison to check current pricing across providers.
Consider locking in supply. Some clinics and pharmacies offer 3-month or 6-month supply options. If your pharmacy allows it, purchasing ahead at current prices is a hedge against Q4 2026 increases. Check whether your current protocol allows stocking ahead without running into controlled substance prescription limits -- testosterone remains a Schedule III controlled substance with refill restrictions in most states.
Watch for enclomiphene as a hedge.Enclomiphene is not a controlled substance and does not face the same supply chain pressures as exogenous testosterone. For men with secondary hypogonadism who want to preserve fertility and reduce supply chain risk, it may be worth discussing with your provider.
For HRT Patients
Diversify away from the patch if possible. If estrogen patches have been hard to fill, the tariff adds another reason to discuss alternatives with your prescriber. Estradiol gel, spray, vaginal rings, and cream deliver estrogen effectively and may face different supply dynamics than patches. See our estrogen patch alternatives guide.
Ask about domestic compounding. Some compounding pharmacies source APIs from domestic manufacturers or have locked in long-term contracts that predate the tariff announcement. These pharmacies may be insulated from the initial cost shock.
Monitor your out-of-pocket costs after October 2026. The second phase of tariffs hits smaller importers on September 29. If your compounding pharmacy or clinic raises prices in Q4 2026, the tariff is the likely driver.
What the Exemptions Mean in Practice
The tariff structure has several carve-outs worth understanding:
Category
Tariff Rate
Notes
Patented branded drugs
100%
Large pharma, effective July 31, 2026
Generic finished drugs
0%
Exempt from Section 232
Bulk APIs (no onshoring plan)
100%
Effective September 29, 2026
Bulk APIs (approved onshoring)
20%
Until April 2030
MFN pricing deal
0%
Until January 2029
For testosterone patients, the most relevant distinction is between generic finished vials (exempt) and bulk API powder (not exempt). If your pharmacy compounds from powder, the tariff applies. If your pharmacy dispenses a commercially manufactured generic vial, it does not.
For estrogen patients, the same logic applies. A commercially manufactured estradiol patch or gel from a domestic generic manufacturer should not see a direct tariff increase. A compounded estradiol cream made from imported API will.
The Bigger Picture
The pharmaceutical tariff is part of a broader trend reshaping hormone therapy access in the United States. The FDA removed black-box warnings from HRT products, signaling a new era of expanded use. The FDA expert panel recommended descheduling testosterone and expanding indications to include age-related hypogonadism. Prescriptions for both testosterone and estrogen are growing at double-digit annual rates.
All of that demand growth is colliding with a supply chain that was never built for this volume, and now faces a new tariff wall on top of existing shortages and capacity constraints.
The patients most likely to feel the squeeze are the ones who depend on compounded hormone therapy -- which is precisely the population served by most online TRT and HRT clinics. Whether the tariff ends up being a temporary negotiating position, a permanent cost increase, or a catalyst for domestic API manufacturing remains to be seen.
In the meantime, understanding where your medication comes from and how the tariff applies to your specific supply chain is the most practical thing you can do.
References
White House Proclamation, April 2, 2026: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States (Section 232)
Health Affairs Scholar, 2026: Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs
Ropes & Gray, April 2026: 100% On Brand: U.S. Imposes New Tariffs (and Key Exemptions) on Patented Pharmaceuticals
CNBC, April 2, 2026: Trump prepares pharmaceutical tariffs of up to 100%
NBC News, May 10, 2026: FDA claims there's no estrogen patch shortage as women struggle to get prescriptions filled
NovaGenix: TRT Costs on the Rise? How Global Tariffs Could Impact Your Wallet
ASHP Drug Shortage Database: Testosterone Cypionate Injection
Possibly. A 100% tariff on imported active pharmaceutical ingredients (APIs) takes effect July 31, 2026 for large manufacturers and September 29, 2026 for smaller ones. Testosterone cypionate and enanthate APIs primarily come from China and India. If those tariffs apply to the raw materials your pharmacy sources, the cost increase will flow through to your monthly prescription. Compounded testosterone from 503A pharmacies is more exposed than branded generics, which are currently exempt from the Section 232 pharma tariff. The actual impact depends on how each supplier and pharmacy absorbs or passes along the increase.
Are generic testosterone products exempt from the tariffs?
Generic finished pharmaceuticals and their associated ingredients are exempt from the Section 232 tariff at this time. That means commercially manufactured testosterone cypionate vials from companies like Hikma, Sun Pharma, or Pfizer should not see a direct tariff-driven price increase. However, compounding pharmacies that import bulk APIs are not covered by the same generic exemption and may face higher raw material costs.
How much could compounded testosterone prices go up?
A Health Affairs Scholar analysis modeled a 100% worldwide API tariff and found an average 30 percent price increase on domestically produced generics using imported APIs. The blended tariff scenario based on proposed country-specific rates showed a 10 percent increase. Compounding pharmacies that currently charge 30 to 60 dollars per vial could see prices rise 5 to 20 dollars per vial depending on their API source, their contract terms, and whether they absorb part of the increase.
Does this affect estrogen and progesterone too?
Yes. The same Health Affairs analysis specifically modeled estrogen, progesterone, and levothyroxine as affected hormone APIs. Estrogen showed a 5.3 percent price increase under the blended tariff scenario. The estrogen patch shortage is already driven by demand outpacing supply. If patch manufacturers face higher API costs on top of that, prices will be even harder to hold.
What can I do to protect against price increases?
Lock in pricing now if your clinic or pharmacy offers multi-month supply options. Ask your pharmacy whether their testosterone API comes from a domestic source or an imported one. Consider whether a branded generic from a large manufacturer, which is currently exempt from the tariff, might be a more price-stable option than compounded medication. Compare pricing across the clinics we track at our [clinic comparison page](/clinics?from=pharma-tariffs-trt-hrt-cost-impact) to find the best value for your protocol.
When do the tariffs actually take effect?
The Section 232 pharmaceutical tariff takes effect July 31, 2026 for the 17 largest pharmaceutical companies identified in the proclamation, and September 29, 2026 for all other importers. Companies with approved US onshoring plans can qualify for a reduced 20 percent rate until April 2030. Companies that negotiate most-favored-nation pricing deals pay zero tariffs until January 2029.
